IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

Not available.

[1]  R. Marcus,et al.  The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma , 2021, Clinical Cancer Research.

[2]  J. Burke,et al.  Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Santoro,et al.  Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. , 2021, Blood advances.

[4]  C. Flowers,et al.  Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. , 2020, Blood advances.

[5]  M. Raderer,et al.  Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B‐cell lymphoma of the mucosa associated lymphoid tissue (MALT‐lymphoma) outside of clinical trials: Real‐world data from the University of Vienna , 2020, Hematological oncology.

[6]  A. Salar,et al.  Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Gribben,et al.  AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Flinn,et al.  DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Calimeri,et al.  Clarithromycin as a “repurposing drug” against MALT lymphoma , 2018, British journal of haematology.

[10]  F. Cavalli,et al.  A MALT lymphoma prognostic index. , 2017, Blood.

[11]  Hua Zhang,et al.  Minimax and admissible adaptive two-stage designs in phase II clinical trials , 2016, BMC Medical Research Methodology.

[12]  C. Huff,et al.  Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma , 2014, American journal of hematology.

[13]  W. Dolak,et al.  A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) , 2013, Haematologica.

[14]  C. Copie-Bergman,et al.  Gela histological scoring system for post‐treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice , 2013, British journal of haematology.

[15]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.